What is the role of everolimus (Afinitor) in the treatment of renal cell carcinoma (RCC)?

Updated: May 21, 2019
  • Author: Kush Sachdeva, MD; Chief Editor: E Jason Abel, MD  more...
  • Print
Answer

Everolimus (Afinitor) is a serine-threonine kinase inhibitor of mTOR. This agent was approved by the FDA in 2009 for use in advanced renal cell carcinoma after failure of treatment with sunitinib or sorafenib.

The recommended everolimus dose for treatment of advanced renal cell carcinoma is 10 mg, to be taken once daily at the same time every day, with or without food. [46] However, the tablets should be swallowed whole, not be chewed or crushed, with a glass of water.


Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!